Condition: Inflammatory Bowel Disease · Crohn's Disease (CD) · Sponsor: The Second Hospital of Nanjing Medical University
The gut microbiota is considered to constitute a "microbial organ" which has pivotal roles in the intestinal diseases and body's metabolism. Evidence from animal and human studies strongly supports the link between intestinal bacteria and inflammatory bowel diseases (IBD). Dozens of studies reported its efficacy in treatment of severe Clostridium difficile colitis. Preliminary studies using fecal microbiota transplantation (FMT) for Ulcerative Colitis (UC), Crohn's diseases (CD), irritable bowel syndrome (IBS) and constipation have also met with some success. However, the results on CD is very limited. This marks the initial step in exploring the potential efficacy of fecal bacteriotherapy for CD. The investigators aim to evaluate the effectiveness, durability, and safety of FMT in a cohort of at least 500 patients with CD over a ten-year period
This description comes directly from the study's public registry record.
Faming Zhang, MD, PhD · 86-025-58509883 · fzhang@njmu.edu.cn
Huijie Zhang, MD, PhD · 86-025-58509670 · zhjssm@163.com
Always discuss trial participation with your own doctor first.
| The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University | Huai'an, Jiangsu, China | Recruiting |
| Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01793831